An engineered fibrinogen variant AαQ328,366P does not polymerise normally, but retains the ability to form α cross-links

Summary

A fibrin clot is stabilised through the formation of factor XIIIa-catalysed intermolecular ε -lysyl-γ -glutamyl covalent cross-links between α chains to form α polymers and between γ chains to form γ dimers. In a previous study we characterised fibrinogen Seoul II, a heterozygous dysfibrinogen in which a cross-linking acceptor site in Aα chain, Gln328, was replaced with Pro (AαQ328P). Following on the previous study, we investigated whether the alteration of Gln residues Aα328 and Aα366 affects fibrin polymerisation and α chain cross-linking. We have expressed three recombinant fibrinogens: AαQ328P, AαQ366P, and AαQ328,366P in Chinese hamster ovary cells, purified these fibrinogens from the culture media and performed biochemical tests to see how the introduced changes affect fibrin polymerisation and α chain cross-linking. Thrombin-catalysed fibrin polymerisation of all variants was impaired with the double mutation being the most impaired. In contrast, sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblot analysis showed α polymer formation with all three engineered proteins. This study demonstrates that AαQ328 and AαQ366 are important for normal fibrin clot formation and in the absence of residues AαQ328 and AαQ366, other Gln residues in the a chain can support FXIIIa-catalysed fibrin cross-linking.

Keywords

Fibrin alpha chain - cross-linking - Glutamine acceptor - AαQ328 - AαQ366

• References

• 1 Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299.
• 2 Tennent GA, Brennan SO, Stangou AJ. et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109: 1971-1974.
• 3 Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29: 177-188.
• 4 Medved L, Weisel JW. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 07: 355-359.
• 5 Doolittle RF, Goldbaum DM, Doolittle LR. Designation of sequences involved in the „coiled-coil“ interdomainal connections in fibrinogen: constructions of an atomic scale model. J Mol Biol 1978; 120: 311-325.
• 6 Lefebvre P, Velasco PT, Dear A. et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103: 2571-2576.
• 7 Koopman J, Haverkate F, Grimbergen J. et al. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA-->stop TAA). Blood 1992; 80: 1972-1979.
• 8 Marchi R, Carvajal Z, Meyer M. et al. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA). Thromb Res 2006; 118: 637-650.
• 9 Collen A, Maas A, Kooistra T. et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-980.
• 10 Furlan M, Steinmann C, Jungo M. et al. A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III. J Biol Chem 1994; 269: 33129-33134.
• 11 Homer VM, Mullin JL, Brennan SO. et al. Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerisation. J Thromb Haemost 2003; 01: 1245-1250.
• 12 Maekawa H, Yamazumi K, Muramatsu S. et al. An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II characterized by impaired fibrin gel formation. J Biol Chem 1991; 266: 11575-11581.
• 13 Park R, Doh HJ, An SS. et al. A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood 2006; 108: 1919-1924.
• 14 Ridgway HJ, Brennan SO, Gibbons S. et al. Fibrinogen Lincoln: a new truncated alpha chain variant with delayed clotting. Br J Haematol 1996; 93: 177-184.
• 15 Ridgway HJ, Brennan SO, Faed JM. et al. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98: 632-639.
• 16 Standeven KF, Carter AM, Grant PJ. et al. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110: 902-907.
• 17 Chen R, Doolittle RF. - cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10: 4487-4491.
• 18 Purves L, Purves M, Brandt W. Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (Bitis arietans) acting at cross-linked sites of the gamma-chain. Sequence of carboxy-terminal cyanogen bromide gamma-chain fragments. Biochemistry 1987; 26: 4640-4646.
• 19 Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 291-311.
• 20 Fretto LJ, Ferguson EW, Steinman HM. et al. Localisation of the alpha-chain cross-link acceptor sites of human fibrin. J Biol Chem 1978; 253: 2184-2195.
• 21 Cottrell BA, Strong DD, Watt KW. et al. Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979; 18: 5405-5410.
• 22 Matsuka YV, Medved LV, Migliorini MM. et al. Factor XIIIa-catalysed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry 1996; 35: 5810-5816.
• 23 Okumura N, Gorkun OV, Lord ST. Severely impaired polymerisation of recombinant fibrinogen gamma-364 Asp --> His, the substitution discovered in a heterozygous individual. J Biol Chem 1997; 272: 29596-29601.
• 24 Gorkun OV, Veklich YI, Weisel JW. et al. The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood 1997; 89: 4407-4414.
• 25 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
• 26 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
• 27 Weisel JW, Nagaswami C. Computer modeling of fibrin polymerisation kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63: 111-128.
• 28 Cierniewski CS, Budzynski AZ. Involvement of the alpha chain in fibrin clot formation. Effect of monoclonal antibodies. Biochemistry 1992; 31: 4248-4253.
• 29 Blumenstein M, Matsueda GR, Timmons S. et al. A beta-turn is present in the 392-411 segment of the human fibrinogen gamma-chain. Effects of structural changes in this segment on affinity to antibody 4A5. Biochemistry 1992; 31: 10692-10698.
• 30 Barlow DJ, Thornton JM. Helix geometry in proteins. J Mol Biol 1988; 201: 601-619.
• 31 von Heijne G. Proline kinks in transmembrane alpha-helices. J Mol Biol 1991; 218: 499-503.
• 32 Veklich YI, Gorkun OV, Medved LV. et al. Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localisation by electron microscopy and the effects of isolated alpha C fragments on polymerisation. J Biol Chem 1993; 268: 13577-13585.
• 33 Tsurupa G, Mahid A, Veklich Y. et al. Structure, stability, and interaction of fibrin alphaC-domain polymers. Biochemistry 2011; 50: 8028-8037.
• 34 Gorkun OV, Veklich YI, Medved LV. et al. Role of the alpha C domains of fibrin in clot formation. Biochemistry 1994; 33: 6986-6997.
• 35 Tsurupa G, Pechik I, Litvinov RI. et al. On the mechanism of alphaC polymer formation in fibrin. Biochemistry 2012; 51: 2526-2538.
• 36 Gorkun OV, Henschen-Edman AH, Ping LF. et al. Analysis of A alpha 251 fibrinogen: the alpha C domain has a role in polymerisation, albeit more subtle than anticipated from the analogous proteolytic fragment X. Biochemistry 1998; 37: 15434-15441.
• 37 Wang W. Identification of respective lysine donor and glutamine acceptor sites involved in factor XIIIa-catalysed fibrin alpha chain cross-linking. J Biol Chem 2011; 286: 44952-44964.